
Gene Techno Science: A Japan-based R&D firm specializing in biopharmaceuticals and oncology treatments.
Kidswell Bio, originally founded as Gene Techno Science in 2001 and headquartered in Sapporo, Japan, is dedicated to the research and development of biopharmaceutical products and biosimilars. The company's core mission is to advance healthcare through innovative treatments for immunological, cardiovascular, ophthalmic, infectious, and renal diseases, alongside oncology. Kidswell Bio offers a range of products, including Filgrastim for cancer treatment, focusing on improving patient outcomes in Japan and potentially globally.
Notable figures associated with Kidswell Bio include its founders and key researchers who have driven its scientific advancements. The company has attracted significant investment from both private and public sectors, reflecting confidence in its innovative potential. Key achievements include the successful development and commercialization of several biopharmaceutical products, contributing to improved healthcare solutions. Kidswell Bio's impact is marked by its commitment to addressing critical medical needs through cutting-edge research and development.

Oncolys BioPharma
oncolys.com

Kyowa Kirin Co.
kyowakirin.com

Katana Pharmaceuticals

SK Bioscience
skbioscience.co.kr

BioRay Pharmaceuticals

BioPro Pharmaceutical

JK BioPharma Solutions

Essex Bio-Technology

Walden Biosciences

Taiho Pharmaceutical Co.
taiho.co.jp

Superior Biologics

Brii Biosciences
briibio.com

Apic Bio

BridGene Biosciences

Biocon
biocon.com
Companies similar to Kidswell Bio include Oncolys BioPharma, Kyowa Kirin Co., Katana Pharmaceuticals and SK Bioscience.
Kidswell Bio was founded in 2001.
Kidswell Bio's headquarters is located in Tokyo, Tokyo, JP.
Kidswell Bio's most recent funding round was for $1.2B (USD) in February 2013.
As of Feb 28, 2013, Kidswell Bio has raised a total of $2.7B (USD).